Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET
NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough.
Conference Call/WebcastThe Company will host a conference call and webcast to review the topline results. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
About Idiopathic Pulmonary Fibrosis (IPF) Chronic CoughChronic cough is a highly prevalent condition in patients with IPF, impacting up to 85% of the IPF population. There are ~140,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.
About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Investor ContactJonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@trevitherapeutics.com
Media ContactRosalia Scampoli914-815-1465rscampoli@marketcompr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
10 hours ago
- Malaysian Reserve
MY DR NOW Launches New Clinic in Glendale, Bringing Hassle-Free Healthcare to the Northwest Valley
GLENDALE, Ariz., June 2, 2025 /PRNewswire/ — The Northwest Valley just got a lot more convenient when it comes to healthcare. MY DR NOW is opening its latest family medicine clinic in Glendale on the southeast corner of 67th Avenue and Happy Valley Road, in the Fry's shopping center at 6625 West Happy Valley Road, Suite 105. Doors open on Monday, June 2nd at 8:00 AM, offering residents a fresh, flexible approach to primary care. This new Glendale location reflects MY DR NOW's continued commitment to redefining how and when people access care. With extended hours, walk-in availability, and same-day appointments every day a week, the clinic is designed to accommodate busy schedules without sacrificing quality. 'Healthcare shouldn't be hard to get,' said Dr. Payam Zamani, Founder and CEO of MY DR NOW. 'We built this clinic to fit into people's lives—not disrupt them. Whether you need care early, late, or last minute, our Glendale location is here to make staying healthy as easy and convenient as it should be.' Whether it's a routine physical, support in managing a chronic condition, or last-minute treatment for a sudden illness, MY DR NOW offers a wide range of family medicine services without the need to plan weeks in advance. The new clinic brings this convenience and care to one of Glendale's most active growth areas, helping residents stay healthy while keeping up with life. MY DR NOW continues to expand across Arizona with one mission: make healthcare more accessible and ridiculously easy. Patients can schedule appointments online at through the MyChart app, or by calling (480) 677-8282. About MY DR NOW MY DR NOW is dedicated to transforming the way primary care is delivered by offering both scheduled appointments and walk-in services at all its clinics. With a strong focus on accessibility and convenience, MY DR NOW provides comprehensive healthcare services, including family medicine, pediatrics, women's health, annual physicals, immunizations, chronic disease management, and prescription refills. The company's innovative approach ensures that everyone in the community can receive high-quality medical care at their convenience, whether at one of its numerous clinic locations, through in-home visits, or via video visits. Media Contact:Glenn JonesBusiness Development MY DR NOW(480) 677-8282info@
New Straits Times
a day ago
- New Straits Times
Vape device interim licence issued by Miti
KUALA LUMPUR: The Health Ministry has clarified that a recent interim licence for manufacturing nicotine-based vape devices was issued by the Investment, Trade and Industry Ministry (Miti). The licence was granted through the Malaysian Investment Development Authority (Mida) under the Industrial Coordination Act 1975 and local licensing laws. This comes after media reports said a Nasdaq-listed company from the United States had received Malaysia's first federal licence to produce nicotine products. The Health Ministry explained that while Miti issues manufacturing licences, the production, import, and sale of nicotine liquids are regulated under the Control of Smoking Products for Public Health Act 2024 (Act 852). Section 2 of the Act defines nicotine liquids—including substances like nicotine, propylene glycol, glycerol, and triethylene glycol—as smoking products. These products can be sold in Malaysia, but they are strictly regulated. The ministry said it is responsible for monitoring the contents and emissions of these products to protect public health. "The regulation of these smoking products also involves other government agencies, including an import control by the Customs Department through restrictions covering raw materials and finished goods under the Customs (Prohibition of Imports) Order 2008. "Among others, device safety standard testing by Sirim, enforced under the Trade Descriptions (Certification and Marking) of Electronic Cigarette Devices (Vape Device) Order 2022 under the Trade Descriptions Act 2011, under the purview of the Domestic Trade and Cost of Living Ministry," the statement read. The Health Ministry stressed that all decisions on vape liquid production and sales are made jointly by relevant authorities and reaffirmed its commitment to strong enforcement and public health safety.
Malaysian Reserve
a day ago
- Malaysian Reserve
Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ — International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set to be a transformative platform that accelerates healthcare innovation, fosters regional collaboration, and drives economic growth throughout the healthcare sector. With over 900 leading local, regional, and international exhibitors showcasing more than 15,000 products and services, and an expected attendance of 21,000 professionals from over 50 countries, IHW 2025 offers unmatched opportunities for networking, knowledge exchange, and business development. One Venue, Five Healthcare Trade Shows, One Unmissable Event IHW 2025 integrates five flagship international trade exhibitions under one roof, covering the entire healthcare value chain and enhancing opportunities to learn, collaborate, invest, and showcase innovations across healthcare sectors, noted Rungphech (Rose) Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets. Each exhibition is complemented by dedicated conferences tailored to the specific needs and developments of their respective industries: CPHI South East Asia – covering the complete pharmaceutical production supply chain. WHX Kuala Lumpur (formerly Asia Health) – focusing on medical devices, hospital services, and healthcare systems. WHX Labs Kuala Lumpur (formerly Medlab Asia) – the premier medical laboratory event in the region. Medtec Southeast Asia – specializing in the design and manufacturing of medical devices and technologies. HIMSS (Healthcare Information and Management Systems Society) – a leading global conference exploring key themes in digital health, including: Artificial Intelligence, Data Innovation, Workforce Transformation, and Equitable Care Delivery. 'Participants at IHW 2025 will have the unique advantage of exploring multiple healthcare sectors and attending 125 conference sessions tailored to diverse healthcare domains – all within a single venue. This integrated format eliminates the need to travel between separate events, allowing attendees to maximise their time and resources while gaining a comprehensive understanding of the latest market trends, innovative technologies, and cutting-edge solutions,' said Rungphech. Malaysia – Leading the Way in Healthcare 'Malaysia's robust healthcare market expansion, flourishing medical tourism sector, strategic regional location, supportive government initiatives, and ongoing advancements in healthcare infrastructure collectively establish the country as an ideal host for IHW 2025. This event will further cement Malaysia's status as a premier healthcare hub in ASEAN and serve as a gateway for global healthcare collaboration,' highlighted Rungphech. As ASEAN Chair in 2025, Malaysia plays a pivotal role in promoting regional healthcare cooperation, addressing critical challenges such as supply chain resilience, digital health adoption, and sustainable health financing through platforms like the EU-ASEAN Health Summit. Strengthening Regional Healthcare Cooperation IHW 2025 is fully aligned with ASEAN's strategic objectives to bolster healthcare systems, enhance health outcomes, and promote equitable access across member states. The event serves as a vital platform for fostering networking and partnerships essential for advancing cross-border collaboration, policy harmonization, and increased investment in healthcare infrastructure and services. This collaborative environment supports key regional initiatives including digital health integration, combating non-communicable diseases, and pandemic preparedness-priorities underscored by recent public health challenges in Southeast Asia. MATRADE: A Strong and Strategic Partner As a valued partner of International Healthcare Week 2025, the Malaysia External Trade Development Corporation (MATRADE), Malaysia's national trade promotion agency, plays a crucial role in enhancing Malaysia's global visibility and reputation in the healthcare sector. Through promotion and fostering international collaborations, MATRADE actively positions Malaysia as a regional medical hub for Southeast Asia and beyond. YB Dato' Seri Reezal Merican Naina Merican, Chairman of MATRADE, emphasized the significance of IHW 2025, stating, 'International Healthcare Week serves as a powerful platform that elevates Malaysia's standing as a regional leader in healthcare and medical services. This leading event not only promotes innovation but also directly contributes to our nation's economic growth by attracting world-class exhibitors, regional and international delegates, and top healthcare experts to Malaysia—fueling trade, knowledge sharing, and industry advancement.' Join Us at IHW 2025 Healthcare professionals are invited to register online at to secure their place at this free-to-attend event. Don't miss this exceptional opportunity to contribute to shaping the future of the vibrant and evolving healthcare industry in ASEAN and beyond! About Informa Markets Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Pharmaceuticals, Boating, Food, Fashion, and Infrastructure. As the world's leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
